Page 110 - Read Online

Sugarbaker. J Cancer Metastasis Treat 2018;4:7 I http://dx.doi.org/10.20517/2394-4722.2017.67 Page 13 of 16

FUTURE PROSPECTS
Beyond the scope of this view are many promising new directions for prevention and treatment of peritoneal
metastases from gastric cancer. Targeted therapies may be of great value for subsets of patients, such as
[76]
those who are HER2-positive (ToGA Study) . Also, pressurized intraperitoneal aerosol chemotherapy may
substitute for NIPS in preparing patients for subsequent potentially curative resection of all clinically evident
[77]
disease . As these new treatments develop controlled trials comparing the new strategies will be necessary.

DECLARATIONS
Authors’ contributions
Sugarbaker PH contributed solely to the paper.

Financial support and sponsorship
None.

Conflicts of interest
There are no conflicts of interest.

Patient consent
Not applicable.

Ethics approval
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Berretta M, Fisichella R, Borsatti E, Lleshi A, Ioffredo S, Meneguzzo N, Canzonieri V, Di Grazia A, Cannizzaro R, Tirelli U, Berretta
S. Feasibility of intraperitoneal Trastuzumab treatment in a patient with peritoneal carcinomatosis from gastric cancer. Eur Rev Med
Pharmacol Sci 2014;18:689-92.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF. Clinical outcomes with laparoscopic stage M1, unresected gastric
adenocarcinoma. Ann Surg 2006;243:189-95.
4. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009;472:467-77.
5. Cappellani A, Zanghi A, Di Vita M, Zanet E, Veroux P, Cacopardo B, Cavallaro A, Piccolo G, Lo Menzo E, Murabito P, Berretta M.
Clinical and biological markers in gastric cancer: update and perspectives. Front Biosci (Schol Ed) 2010;2:403-12.
6. Hioki M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kinoshita T. Predictive factors improving survival after gastrectomy in
gastric cancer patients with peritoneal carcinomatosis. World J Surg 2010;34:555-62.
7. Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of
treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003;21:233-48.
8. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and
intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219-28.
9. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis
treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French
study. J Clin Oncol 2010;28:63-8.
10. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL,
Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal
mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237-42.
11. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol
2006;7:69-76.
12. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look)
clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
13. Wisbeck WM, Becher EM, Russell AH. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the
radiation oncologist. Radiother Oncol 1986;7:13-8.